uBriGene Biosciences
uBriGene provides lentiviral process development, GMP manufacturing, and regulatory support for Cellinfinity’s in vivo CAR-T programs. Its manufacturing partnership establishes an enabling role; it does not establish ownership of the therapeutic candidates.
Corporate information
- Company entity
- uBriGene Biosciences
- Headquarters / principal office
- Germantown, Maryland, USA; Richmond, British Columbia, CanadaOffice location disclosed on the corporate website; a sole legal or global headquarters is not inferred. ↗
- Founded
- 2015 ↗
- Ownership / capital status
- PrivateSeries C+ (2023 historical disclosure) ↗
- Official corporate reference
- https://www.ubrigene.com/news-events/ubrigene-cellinfinity-in-vivo-car-t-partnership/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2023-04-20 · Series C+ · CNY 150 million (company also states USD20 million) ↗
Uses the source CNY amount; company also quotes USD20 million. No current exchange-rate conversion is applied.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
uBriGene provides lentiviral process development, GMP manufacturing, and regulatory support for Cellinfinity’s in vivo CAR-T programs. Its manufacturing partnership establishes an enabling role; it does not establish ownership of the therapeutic candidates.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- uBriGene Biosciences — primary program / ownership disclosure
- uBriGene Biosciences — official company page
- uBriGene official company background — founded 2015
- Official company contact / corporate location disclosure